MX2022008099A - Tratamiento para el cancer con inhibidores de cdk12/13. - Google Patents

Tratamiento para el cancer con inhibidores de cdk12/13.

Info

Publication number
MX2022008099A
MX2022008099A MX2022008099A MX2022008099A MX2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A
Authority
MX
Mexico
Prior art keywords
cancer
cdk12
inhibitors
treatment
compositions
Prior art date
Application number
MX2022008099A
Other languages
English (en)
Inventor
Elisabeth Gardiner
Eric A Murphy
Toufike Kanouni
Eric Martin
John Tyhonas
Lee D Arnold
Noelito Timple
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of MX2022008099A publication Critical patent/MX2022008099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan composiciones y métodos para el tratamiento de cáncer de mama triple negativo, cáncer de ovario y cáncer de próstata resistente a la castración. Dichas composiciones comprenden inhibidores de CDK12/13.
MX2022008099A 2019-12-31 2020-12-23 Tratamiento para el cancer con inhibidores de cdk12/13. MX2022008099A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962956114P 2019-12-31 2019-12-31
PCT/US2020/066967 WO2021138215A1 (en) 2019-12-31 2020-12-23 Treatment of cancer with cdk12/13 inhibitors

Publications (1)

Publication Number Publication Date
MX2022008099A true MX2022008099A (es) 2022-07-11

Family

ID=76686778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008099A MX2022008099A (es) 2019-12-31 2020-12-23 Tratamiento para el cancer con inhibidores de cdk12/13.

Country Status (11)

Country Link
US (1) US20230074545A1 (es)
EP (1) EP4085053A4 (es)
JP (1) JP2023508996A (es)
KR (1) KR20220123064A (es)
CN (1) CN115175899A (es)
AU (1) AU2020417223A1 (es)
BR (1) BR112022012867A2 (es)
CA (1) CA3166386A1 (es)
IL (1) IL294392A (es)
MX (1) MX2022008099A (es)
WO (1) WO2021138215A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
EP4568954A1 (en) * 2022-08-08 2025-06-18 Insilico Medicine IP Limited Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof
JP2026507677A (ja) * 2023-02-24 2026-03-04 シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ Ｃｄｋ１２／１３のアリール置換基含有分解剤、その調製方法、ならびにその医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
CN103119054B (zh) * 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US9125899B1 (en) * 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2015058163A2 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
HRP20211466T1 (hr) * 2015-12-09 2021-12-24 Medizinische Universität Wien Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka
HRP20240136T1 (hr) * 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
WO2019213403A1 (en) * 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) * 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
EP3897612A1 (en) * 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor

Also Published As

Publication number Publication date
BR112022012867A2 (pt) 2022-09-06
CN115175899A (zh) 2022-10-11
EP4085053A4 (en) 2023-12-27
IL294392A (en) 2022-08-01
KR20220123064A (ko) 2022-09-05
JP2023508996A (ja) 2023-03-06
CA3166386A1 (en) 2021-07-08
EP4085053A1 (en) 2022-11-09
WO2021138215A1 (en) 2021-07-08
US20230074545A1 (en) 2023-03-09
AU2020417223A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
SA521421744B1 (ar) علاج مناعي توليفي للسرطان
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551923A1 (en) Methods and compositions for treating cancer
NZ754865A (en) Combination therapy for the treatment of cancer
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2019003938A (es) Compuestos espirociclicos.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP4317422A3 (en) Combinatorial cancer immunotherapy
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2022005780A (es) Moduladores de receptores estrogenicos.
TN2019000210A1 (en) Antitumoral compounds
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
PH12019502197A1 (en) Macrocyclic compound and uses thereof
MX379622B (es) Compuestos espirociclicos
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MY200161A (en) Bacteria for targeting tumors and treating cancer